Floatz logo

172 assets in Refractory Malignant Neoplasm

Therapeutic assets addressing Refractory Malignant Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Catequentinib
Refractory Malignant Neoplasm
Nanfang Hospital, Southern Medical UniversityP3BB (70)
Irinotecan
Refractory Malignant Neoplasm
M.D. Anderson Cancer CenterP2BB (68)
Cediranib
Refractory Malignant Neoplasm
National Cancer Institute (NCI)P2BB (65)
Nivolumab
Refractory Malignant Neoplasm
CatalYm GmbHP2BB (64)
Olaparib
Refractory Malignant Neoplasm
Fundación de investigación HMP2BB (64)
Sugemalimab
Refractory Malignant Neoplasm
Second Affiliated Hospital of Soochow UniversityP2BB (64)
Atezolizumab
Refractory Malignant Neoplasm
Bionoxx Inc.P2B (63)
Gm-Csf
Refractory Malignant Neoplasm
Second Affiliated Hospital of Soochow UniversityP2B (63)
Adavosertib
Refractory Malignant Neoplasm
National Cancer Institute (NCI)P2B (62)
Palbociclib
Refractory Malignant Neoplasm
Brown UniversityP2B (62)
Crizotinib
Refractory Malignant Neoplasm
Massachusetts General HospitalP2B (61)
Nilotinib
Refractory Malignant Neoplasm
National Cancer Institute (NCI)P2B (61)
Selumetinib
Refractory Malignant Neoplasm
National Cancer Institute (NCI)P2B (61)
Sorafenib
Refractory Malignant Neoplasm
St. Jude Children's Research HospitalP1/2B (61)
Tocilizumab
Refractory Malignant Neoplasm
University Health Network, TorontoP4B (61)
Lenvatinib
Refractory Malignant Neoplasm
Tongji HospitalP2B (60)
Pembrolizumab
Refractory Malignant Neoplasm
GV20 TherapeuticsP2B (60)
Trametinib
Refractory Malignant Neoplasm
Shanghai Chest HospitalP2B (60)
Adriamycin
Refractory Malignant Neoplasm
BeOne MedicinesP2B (59)
Binimetinib
Refractory Malignant Neoplasm
N.N. Petrov National Medical Research Center of OncologyP2B (59)
Talazoparib
Refractory Malignant Neoplasm
St. Jude Children's Research HospitalP2B (59)
Teclistamab
Refractory Malignant Neoplasm
University Health Network, TorontoP4B (59)
Cabozantinib
Refractory Malignant Neoplasm
M.D. Anderson Cancer CenterP2B (58)
Carboplatin
Refractory Malignant Neoplasm
OHSU Knight Cancer InstituteP2B (58)
Oxaliplatin
Refractory Malignant Neoplasm
M.D. Anderson Cancer CenterP2B (58)
Pertuzumab
Refractory Malignant Neoplasm
OHSU Knight Cancer InstituteP2B (58)
Relatlimab
Refractory Malignant Neoplasm
Australian & New Zealand Children's Haematology/Oncology GroupP2B (58)
Rituximab
Refractory Malignant Neoplasm
BeOne MedicinesP2B (58)
Sapanisertib
Refractory Malignant Neoplasm
M.D. Anderson Cancer CenterP2B (58)
Trastuzumab
Refractory Malignant Neoplasm
OHSU Knight Cancer InstituteP2B (58)
Trastuzumab Emtansine
Refractory Malignant Neoplasm
OHSU Knight Cancer InstituteP2B (58)
Vemurafenib
Refractory Malignant Neoplasm
OHSU Knight Cancer InstituteP2B (58)
Vismodegib
Refractory Malignant Neoplasm
OHSU Knight Cancer InstituteP2B (58)
177lu-dota-eb-fapi radionuclide therapy
Refractory Malignant Neoplasm
The First Affiliated Hospital of Xiamen UniversityP2B (57)
Dabrafenib
Refractory Malignant Neoplasm
OHSU Knight Cancer InstituteP2B (57)
Dasatinib
Refractory Malignant Neoplasm
OHSU Knight Cancer InstituteP2B (57)
Fexagratinib
Refractory Malignant Neoplasm
National Cancer Institute (NCI)P2B (57)
PI3K/MTOR INHIBITOR LY3023414
Refractory Malignant Neoplasm
National Cancer Institute (NCI)P2B (57)
Tazemetostat
Refractory Malignant Neoplasm
National Cancer Institute (NCI)P2B (57)
Tiragolumab
Refractory Malignant Neoplasm
National Cancer Institute (NCI)P2B (57)
Fludarabine
Refractory Malignant Neoplasm
National Cancer Institute (NCI)P2B (56)
Regorafenib
Refractory Malignant Neoplasm
China Medical University, ChinaP1/2CCC (55)
Selinexor
Refractory Malignant Neoplasm
National University Hospital, SingaporeP1/2CCC (55)
Zanubrutinib
Refractory Malignant Neoplasm
BeOne MedicinesP2CCC (55)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
Refractory Malignant Neoplasm
National Cancer Institute (NCI)P2CCC (53)
Benmelstobart
Refractory Malignant Neoplasm
Nanfang Hospital, Southern Medical UniversityP2CCC (53)
Capivasertib
Refractory Malignant Neoplasm
National Cancer Institute (NCI)P2CCC (53)
Ceralasertib
Refractory Malignant Neoplasm
National Cancer Institute (NCI)P2CCC (53)
Copanlisib
Refractory Malignant Neoplasm
OHSU Knight Cancer InstituteP2CCC (53)
Defactinib
Refractory Malignant Neoplasm
National Cancer Institute (NCI)P2CCC (53)
Showing 1 to 50 of 172 assets
PreviousPage 1 of 4Next